Molecular analysis of genetic mutations among cross-resistant second-line injectable drugs reveals a new resistant mutation in Mycobacterium tuberculosis
Loading...
Date
Authors
Malinga, Lesibana Anthony
Brand, Jeannette
Olorunju, Steve
Stoltz, Anton Carel
Van der Walt, Martie
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Mutations causing mono and cross-resistance among amikacin, kanamycin and capreomycin of second-line injectable
drugs (SLIDs) namely are not well understood.We investigated 124 isolates of Mycobacterium tuberculosis
for mutations within rrs, eis, tlyA and efflux pump (Rv1258c and Rv0194) genes involved in resistance
towards SLIDs. The distribution of mutations across these genes were significantly different in strains with
mono-resistance or cross-resistance. A new mutation G878A was found in rrs gene, among strains with
capreomycin mono-resistant, or in strains with cross-resistance of capreomycin, kanamycin and amikacin. This
mutation was associated with the Euro-American X3 lineage (P b 0.0001). Mutations in the two efflux genes
Rv1258c and Rv0194 were confined to strains with only capreomycin/amikacin/kanamycin cross-resistance.
Wefurther investigated the minimuminhibitory concentration of capreomycin on isolateswith newG878Amutation
ranging from 8 μg/mL to 64 μg/mL. Inclusion of G878A on new molecular assays could increase the sensitivity
of capreomycin resistance detection.
Description
Keywords
rrs Gene, G878A mutation, Cross-resistance, Second-line injectable drugs (SLIDs), Mycobacterium tuberculosis (MTB)
Sustainable Development Goals
Citation
Malinga, L, Brand, J, Olorunju, S, Stoltz, A & Van der Walt, M 2016, 'Molecular analysis of genetic mutations among cross-resistant second-line injectable drugs reveals a new resistant mutation in Mycobacterium tuberculosis', Diagnostic Microbiology and Infectious Disease, vol. 85, no. 4, pp. 433-437.